◼ Archived
Business
🔮 fades ✓
Bristol Myers claims Phase 2 success for GPRC5D-directed CAR-T
Bristol Myers Squibb reports successful Phase 2 results for its next-generation GPRC5D-directed CAR-T therapy targeting heavily treated myeloma patients.